Skip to main content
Premium Trial:

Request an Annual Quote

Genedata Licenses PathoLead to Novartis Institute for Tropical Diseases

NEW YORK, June 30 (GenomeWeb News) - Genedata today said that the Novartis Institute for Tropical Diseases in  Singapore will use its Phylosopher PathoLead software to study progressive infectious and parasitic disease.


Specifically, the Phylosopher software will serve as an organization-wide scientific management system for proprietary data integration.


Scientists at NITD will use the software to identify and validate target candidates and prioritize the development of drug classes. Research at NITD focuses on Dengue fever and tuberculosis. The ultimate goal would be to develop an anti-viral treatment, the group said.


Almost exactly two years ago, Basel, Switzerland-based Genedata licensed the PathoLead suite of tools to Novartis' Institutes for BioMedical Research.

The Scan

Omicron's Emergence

The World Health Organization has called Omicron a SARS-CoV-2 "variant of concern," the Los Angeles Times writes.

Not as Much

Merck's pill to treat COVID-19 reduces the risk of hospitalization and death among COVID-19 patients by less than previously reported, the New York Times says.

Bats That Hang Together

Discover magazine writes that researchers have found a social microbiome among vampire bats.

PLOS Papers on CEWAS, Simian Varicella Virus Transcriptome, Dermatomyositis Markers

In PLOS this week: multi-omic approach to home in on genetic risk variants, transcriptomic analysis of the simian varicella virus, and more.